secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0000950170-23-012240
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Erasca announces departure of CMO Wei Lin, promotion of Shannon Morris as new CMO
--------------------------------------------------------------------------------

- CMO Wei Lin resigned to pursue other opportunities; last day April 21, 2023, no disagreement cited.
- Shannon Morris, former SVP Clinical Development, promoted to CMO effective April 10, 2023.
- Dr. Morris brings 20+ years oncology experience; led Cosela NDA at G1 Therapeutics and Imfinzi BLA at MedImmune.
- New employment terms: base salary $470,000, 40% target bonus, and option to purchase 375,000 shares vesting monthly.
- Dr. Morris reclassified from Tier 2 to Tier 1 Covered Employee under Severance Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023012240/0000950170-23-012240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023012240/eras-20230404.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-012240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer